What is SYK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SYK.

Stock Ratings / Health Care / SYK / options

MMM (63) BSX (62) BDX (67) MDLN (45) ⌘ Pro Terminal →

Stryker Corporation (SYK) Options Positioning, Max Pain & Unusual Sweeps

$291.86 -6.38% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $287.95

Stryker Corporation (SYK) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $111.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SYK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SYK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Stryker Corporation (NYSE: SYK) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $291.86 (-6.38% 1D, market cap $111.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SYK ranks #122 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SYK compare to MMM and BSX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SYK carries a Roarable C (64/100 RQD), trailing P/E of 36.8x, gross margin of 64.0%, and ROIC of 11.6%. By comparison, MMM (3M Company) holds a C grade (63/100 RQD, P/E 28.2x, ROIC 32.9%, cap $90.09B) and BSX (Boston Scientific Corporation) posts a C grade (62/100 RQD, P/E 22.0x, ROIC 9.2%, cap $60.84B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SYK?

▼

Per SYK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310764), Stryker Corporation generated $25.12B in revenue (+11.2% YoY), $3.25B in net income, and $4.28B in free cash flow against $47.84B in total assets and $14.86B in total debt. Key quantitative strengths: Strong cash generator (64% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $287.95 (-1.34%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 17.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYK)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY SYK SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 17.1% FCF Margin ($4.28B FCF) & 64% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 4.46 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (47.3) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$281.62+5.7% Next Q

Q2 (-2Q)

Grade C$297.60+2.2% Next Q

Q3 (-1Q)

Grade C$304.00-4% Next Q

Current

Grade C$291.86+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SYK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, SYK faces multiple-compression risk if 36.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 61.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($291.26) or 200D SMA ($322.97) invalidates the momentum regime and cuts Target Base ($299.74) toward Bear Floor ($233.80).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SYK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SYK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±6.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SYK)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SYK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating SYK & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on SYK
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SYK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.34%▼ DESCENDING CHANNEL

2026-11-03O $311.8H $311.8L $291.9C $291.9VOL 6.44M

RES: $310.4SUP: $254.0SMA50: $291.3SMA200: $323.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYK Butterfly Map → + Track SYK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

28.3%/yr Implied 5Y Growth

vs. +11.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SYK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SYK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYK)

Health Care Rank #122 of 1016 ⚔️ MMM vs SYK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYK vs. MMM, BSX, BDX, MDLN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Stryker Corporation (SYK) ranks #122 by composite RQD confidence (64/100, grade C) and #21 by equity capitalization ($111.95B). Within this direct 5-issuer industry benchmark cohort, BSX leads on earnings valuation at 22.0x trailing P/E, while MMM leads on capital efficiency and profitability with 32.9% ROIC and 39.9% gross margin. BDX currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with SYK at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SYK ACTIVE Stryker Corporation	C	64/100	36.8x	64.0%	11.6%	-6.38%	$111.95B	Benchmark Subject
MMM 3M Company	C	63/100	28.2x	39.9%	32.9%	-1.70%	$90.09B	/mmm-vs-syk →
BSX Boston Scientific Corporation	C	62/100	22.0x	69.0%	9.2%	-1.66%	$60.84B	/bsx-vs-syk →
BDX Becton Dickinson and Company	C+	67/100	32.2x	45.4%	4.9%	-0.23%	$53.90B	/bdx-vs-syk →
MDLN Medline Inc.	D	45/100	—	—	8.2%	+0.38%	$42.23B	/mdln-vs-syk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000310764

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stryker Corporation (SYK) reported GAAP revenue of $25.12B (+11.2% vs. FY2024 revenue of $22.59B , and +22.5% cumulative change since FY2023) , GAAP net income of $3.25B, operating cash flow of $5.04B, and free cash flow of $4.28B (+22.8% YoY). On the balance sheet, SYK closed FY2025 with $47.84B in total assets against $14.86B in total debt (Altman Z-Score: 4.46, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$25.12B	$3.25B	$5.04B	$4.28B	$47.84B	$14.86B
FY2024 (FY)	2024-12-31	$22.59B	$2.99B	$4.24B	$3.49B	$42.97B	$12.19B
FY2023 (FY)	2023-12-31	$20.50B	$3.17B	$3.71B	$2.79B	$65.77B	$15.39B

3. SYK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SYK compare to MMM and BSX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SYK?

Where is SYK trading relative to its 50-day, 200-day, and 52-week technical levels?

SYK last traded at $291.86 (-6.38% on volume of 6,438,161 shares), positioning the stock +0.21% above its 50-day simple moving average ($291.26) and -9.63% below its 200-day simple moving average ($322.97). Across its 52-week range of $267.00 to $389.33, SYK sits at the 20.3% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($273.18 to $310.54).

Direct Sub-Reports: SYK RQD Cockpit SYK 12M Forecast SYK Earnings & Move SYK Dividends & DRIP SYK Insiders & 13F SYK Whale Options SYK Profit Sankey SYK News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SYK — Stryker Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:09:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SYK scores 67 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are: Fundamental Cash Engine 16/20 (ROIC 11.6%; FCF yield 3.58%), Whale 13F Flow 13/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.13; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 4.46; Piotroski F 9/9; Debt/Equity 0.66).

Investor implications: the strongest pillars are cash generation and balance-sheet forensics, which support the view that the business is financially sound. The weakest pillar is macro regime fit, where a beta of 1.13 indicates the stock has historically moved somewhat more than the market, creating exposure to broader risk-off periods. The valuation tradeoff is visible in the market data: a P/E (TTM) of 36.8 and an EV/EBITDA of 23.6 are premium multiples, and the FCF yield of 3.58% is modest, so upside depends on continued earnings growth rather than a cheap entry point. The verdict's "Watch for Breakout" language signals the rating sees the stock as neutral today, with a potential move higher contingent on catalysts rather than current pricing.

Business

Stryker Corporation is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry,

Recent Catalysts & News Wire Analysis

The news wire contains six items, all tagged to SYK:

GREEN / CATALYST: "Is Stryker Corp. (SYK) Positioned for Above-Market Growth?" (Yahoo Finance) and "Stryker: This Dividend Aristocrat Is Finally Cheap Again" (Seeking Alpha). Both are flagged as potential positive catalysts; the second headline's framing suggests a valuation argument, which should be weighed against the premium multiples in the market data.
YELLOW / MARKET WIRE: "Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5" (TradingKey), "Stryker Stock Price Forecast. Should You Buy SYK?" (StockInvest.us), and "Stryker (SYK) vs Boston Scientific (BSX)" (Yahoo Finance). These are neutral-status market commentary.
RED / RISK WATCH: "Stryker Shares Fall 11.8% After Hours After Q3 Earnings Miss" (Benzinga). This is the single risk-flagged item and the most important near-term item to reconcile against the bullish headlines.

The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

The Butterfly Supply-Chain Graph contains no upstream or downstream links, no sector correlations, and no proprietary signals for SYK. The only sector-level context available is the Health Care classification and the Benzinga-reported Q3 earnings miss referenced in the news wire, which is not linked to any named supplier or customer in the sources.

Analyst View & Smart Money Ownership

The analyst_data section is NONE and the holders section is NONE, so no consensus rating, price targets, Form 4 insider trades, 13F whale holdings, or Congressional trades are reported here. The RQD insider and whale pillars (14/20 and 13/20) reflect flow activity referenced in the rating, but no underlying holder records are provided to verify them.

Open Questions

What drove the reported Q3 earnings miss and the 11.8% after-hours decline, and how does it reconcile with the FY 2025 growth shown in the SEC financials?
Why is FY 2023 cash and EPS unavailable, and can the EPS gap across all three periods be filled from the filings?
What is the composition of the rise in debt from $12.19B to $14.86B, and how does it affect the 0.66 Debt/Equity reading?
Which institutional holders and insider transactions underlie the 13/20 whale and 14/20 insider pillar scores?
What product, customer, and supplier relationships connect SYK to the broader Medical/Dental Instruments industry?

SYK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Stryker Corporation (SYK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SYK Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 20h ago

Is Stryker Corp. (SYK) Positioned for Above-Market Growth?

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 23h ago

Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5: Facts Behind the Movement

TradingKey report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Stryker: This Dividend Aristocrat Is Finally Cheap Again (NYSE:SYK)

Seeking Alpha report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Stryker Stock Price Forecast. Should You Buy SYK?

StockInvest.us report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 1d ago

Stryker Shares Fall 11.8% After Hours After Q3 Earnings Miss - Stryker (NYSE:SYK)

Benzinga report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GuruFocus • 1d ago

Stryker Corporation (SYK) Shares Drop 13% After Q3 Earnings Miss and Lowered Guidance

GuruFocus report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Stryker (SYK): Near-Term Growth Concerns Overshadow Long-Term Strength

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SYK Bull vs. Bear Conversation Board — What's Your Call at $291.86?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SYK 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $336.69 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SYK (C+ • RQD 67/100) a Buy at $311.75?

Welcome to the SYK (Stryker Corporation) Roar Pit. Current RQD Composite is 67/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (36.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $233.81 (-25.0%)

Spot @ $311.75

Pump the brakes on SYK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SYK, but look at what you are paying: 36.8x trailing P/E with 64.0% gross margins. Unless Stryker Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $367.87 (+18.0%)

Spot @ $311.75

SYK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SYK, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $311.75 (52-wk range $267.00 - $389.33), any beat on forward guidance forces shorts and underweight funds to chase.